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Abstract Reactions between the cationic triangular met-
allaprism [(p-cymene)6Ru6(tpt)2(dhnq)3]
6? ([1]6?) [tpt is
2,4,6-tri(pyridine-4-yl)-1,3,5-triazine; dhnq is 5,8-dihy-
droxy-1,4-naphthoquinonato] and Arg, His, Lys, ascorbic
acid, lactic acid and glutathione (GSH) have been studied at
37 C in aqueous solution at pD 7 using NMR spectroscopy
and electrospray ionisation mass spectrometry. Coordination
to the imidazole nitrogen atom of His or to the basic NH/NH2
groups in Arg and Lys slowly displaces the dhnq and tpt
ligands from the (p-cymene)Ru units, and subsequently
additional coordination to the amino and carboxylato groups
forms stable N,N,O metallacycles. Compared with our
previously reported study with the analogous metallaprism
[(p-cymene)6Ru6(tpt)2(dhbq)3]
6? ([2]6?) (dhbq is 2,5-dihy-
droxy-1,4-benzoquinonato), the larger metallaprism [1]6?
appears to be significantly more stable, and disassembled in
the presence of Arg, His and Lys after only 12 h of incuba-
tion. Moreover, the reaction with His is not complete, since
only 14 % of His reacted after more than 1 week of incuba-
tion. Solutions of [1]6? are also able to catalyse oxidation of
the thiol group of Cys and GSH to give the corresponding
disulfides and of ascorbic acid to give the corresponding
dehydroascorbic acid. However, the results are markedly
different from those obtained with metallaprism [2]6?: the
oxidation of Cys and ascorbic acid is not complete, and the
formation of intermediate adducts could be evidenced. On the
other hand, the oxidation of GSH remains fast and is com-
pleted after only 12 h. Oxidation of GSH to give the corre-
sponding disulfide may explain its higher in vitro anticancer
activity as compared with [2]6?. Our results suggest that
metallaprism [1]6? is more robust than [2]6?, may remain
intact in the bloodstream and, therefore, may enter cancer
cells undamaged, thus confirming the drug delivery potential
for such water-soluble organometallic cages.
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Abbreviations
acac Acetylacetonate
dhbq 2,5-Dihydroxy-1,4-benzoquinonato
dhnq 5,8-Dihydroxy-1,4-naphthoquinonato
DOSY Diffusion-ordered spectroscopy
en Ethylenediamine
ESI Electrospray ionisation
GSH Glutathione
GSSG Oxidised glutathione
tpt 2,4,6-Tri(pyridine-4-yl)-1,3,5-triazine
Introduction
The development of new metal anticancer compounds has
always been a challenge for inorganic and organometallic
chemists. Indeed, since the opportune discovery of the
biological activity of cisplatin by Rosenberg et al. [1],
almost four decades of intensive research in this field has
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produced only a small number of clinically used com-
pounds, and currently only platinum derivatives for cancer
treatments [2–4]. However, with the knowledge acquired
during these four decades, medicinal inorganic chemistry
and bioorganometallic chemistry are probably advanced
enough to make significant steps forward and there are
great expectations for the future.
Ruthenium complexes have been known for a long time
to possess anticancer properties [5–7], but it was shown
only recently that these compounds have several advanta-
ges compared with commonly used platinum drugs.
Ruthenium complexes are generally more selective
towards cancer cells and therefore cause fewer side effects
than cisplatin [3]. Phase I clinical trials have already been
completed for two inorganic ruthenium-based drugs,
namely NAMI-A and KP1019 [4]. Phase II clinical trials
have already started for NAMI-A and will soon start for
KP1019 [4, 8, 9]. These two compounds possess similar
structural features but have very different activity towards
cancerous tissue. NAMI-A is most effective against lung
metastases, whereas KP1019 is used to treat colon
carcinomas.
Since the discovery of the enhanced permeability and
retention effect in 1986 [10], the design of supramolecular
assemblies of various sizes and functionalities has gener-
ated a lot of attention [11–14]. The literature shows many
different approaches towards combining transition metal
ions with different polydentate ligands to produce large
metalla assemblies [15–17]. Our group has designed hexa-
cationic ruthenium metallaprisms able to encapsulate
reversibly inside the cavity of planar aromatic molecules or
even planar metal complexes such as Pt(acac)2 or Pd(acac)2
(acac is acetylacetonate) [18–20]. The encapsulated metal
complexes remain stable, with the physical properties of the
prism being retained following encapsulation. Interestingly,
the activity (IC50 = 23 lM) of the metallaprism against the
A2780 cancer cell line significantly increases with the
encapsulation of Pt(acac)2 or Pd(acac)2 (IC50 of 12 and
1 lM, respectively), suggesting transport and leaching of
the guest once it is inside the cell [18].
In a recent study [21], we investigated the behaviour
of the hexacationic metallaprism [Ru6(p-cymene)6(dhbq)3
(tpt)2]
6? ([2]6?) [dhbq is 2,5-dihydroxy-1,4-benzoquino-
nato; tpt is 2,4,6-tri(pyridine-4-yl)-1,3,5-triazine] with
regard to different biological ligands. We showed that the
arene ruthenium metallaprism disassembles upon the addi-
tion of Arg, Lys and His and forms stable mononuclear
chelate adducts. On the other hand, the metallaprism
remained inert towards Met, which is in contrast to what was
observed for previously reported ruthenium complexes,
which formed stable adducts with Met [22, 23]. Interest-
ingly, the metallaprism was also able to catalyse the oxi-
dation of ascorbic acid, Cys and glutathione (GSH) to form
dehydroascorbic acid, cystine and oxidised GSH (GSSG),
respectively. This mode of action involving redox processes
and oxidation of GSH, which is supposed to be at least partly
at the origin of the observed cytotoxicity of some ruthenium
complexes [24], has been rarely reported so far [25, 26].
In this study, we report the reactions of a larger hexa-
cationic metallaprism, [Ru6(p-cymene)6(dhnq)3(tpt)2]
6?
([1]6?) (dhnq is 5,8-dihydroxy-1,4-naphthoquinonato),
with a series of biological ligands, and as compared with
[2]6? [21], this metallaprism contains a dhnq moiety
instead of dhbq. These investigations have been undertaken
to clarify the much better cytotoxicity of this prism
(IC50 of 2 lM with regard to the A2780 cancer cell line
[27] and 23 lM for the prism containing dhbq moieties)
and to verify its relative reactivity and stability upon the
addition of biological ligands.
Materials and methods
Chemicals obtained from commercial suppliers were used
as received and were of analytical grade. RuCl3nH2O was
obtained from Johnson Matthey, D,L-lactic acid, L-Arg, L-
Cys, L-His and L-Lys were purchased from Acros, GSH
was obtained from Sigma-Aldrich and L-ascorbic acid was
obtained from Ha¨nseler.
If not stated otherwise, all experiments were performed
by mixing solutions of the metallaprism [1][CF3SO3]6
(2 mg) in 1.0 mL D2O with 10 equiv of the different
ligands. All reactions were first monitored by 1D 1H NMR
spectroscopy. Two-dimensional homonuclear 1H–1H and
heteronuclear 1H–13C NMR experiments were performed
once the steady state had been confirmed from the 1H NMR
spectra. All experiments on [1]6? and biological ligands
were undertaken at pD 7, i.e. close to the pH value of the
bloodstream. The pD values of D2O solutions were
obtained by use of a glass electrode and addition of 0.4 to
the pH meter reading [28, 29]. The aim of this work was to
study the interactions between [1]6? and biological ligands
in conditions close to physiological conditions; thus, oxy-
gen was not excluded from the solutions.
NMR spectroscopy
NMR data were acquired at 37 C using a Bruker Avance
II 500-MHz NMR spectrometer or a Bruker Avance II
400-MHz NMR spectrometer, both equipped with an
inverse dual channel (1H, X) z-gradient probehead
(broadband inverse). One-dimensional 1H NMR data were
measured with 16–64 transients into 32 k data points over a
width of 15 ppm using a classic presaturation to eliminate
the water resonance. A relaxation delay of 6 s was applied
between transients.
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Two-dimensional 1H–1H NMR correlation spectroscopy
data were acquired over a frequency width of 12 ppm in
both F2 and F1 into 2 k complex data points in F2 (acqui-
sition time 213 or 170 ms) using 128 or 256 t1 increments.
A relaxation delay of 2 s between transients was used for
all experiments. The data were recorded using four or eight
transients, depending on the samples. The water resonance
was suppressed by means of a presaturation routine.
Two-dimensional 1H–13C heteronuclear single quantum
coherence NMR data were acquired over an F2 frequency
width of 12 ppm into 2 k complex data points (acquisition
time 213 or 170 ms). Sixteen to 32 transients were accu-
mulated for each of 196 t1 increments over an F1 frequency
width of 180 ppm centred at 90 ppm. Phase-sensitive data
were acquired in a sensitivity-improved manner using an
echo–antiecho acquisition mode.
Two-dimensional 1H–13C heteronuclear multiple bond
correlation NMR data were acquired over an F2 frequency
width of 12 ppm into 2 k complex data points (acquisition
time 213 or 170 ms). Sixty-four to 96 transients were
accumulated for each of 196 t1 increments over an F1
frequency width of 200 ppm centred at 100 ppm. Phase-
sensitive data were acquired in a sensitivity-improved
manner using an echo–antiecho acquisition mode.
Two-dimensional 1H diffusion-ordered spectroscopy
(DOSY) NMR data were acquired with a standard longi-
tudinal encode–decode pulsed-field-gradient stimulated
echo sequence containing bipolar gradients [30, 31]. For all
experiments, the airflow was increased to 670 l/min, and
the NMR tube was spun. Experimental parameters were
D = 100 ms (diffusion delay), s = 1 ms (gradient recov-
ery delay) and T = 5 ms (eddy current recovery delay).
For each data set, 4 k complex points were collected, and
the gradient dimension was sampled by means of 32
experiments in which the gradient strength was linearly
increased from 1.0 to 50.8 G/cm. The gradient duration d/2
was adjusted to observe a near-complete signal loss at
50.8 G/cm. Typically, the d/2 delay was chosen in the
1.6–2.0-ms range. A 2-s recycle delay was used between
scans for the data shown. For each data set, the spectral
axis was processed with an exponential function (3–5-Hz
line broadening), and a Fourier transform was applied to
obtain 8 k real points. The DOSY reconstruction was rea-
lised with 8 k complex points in the detection dimension
and with 256 points in the diffusion dimension. The
number of scans ranged from 16 to 64 and was adapted to
each sample. All NMR data were processed using TopSpin
(versions 2.1 or 3.0, Bruker, Switzerland).
Electrospray ionisation mass spectrometry
Mass-spectrometric analyses were performed with an LTQ
Orbitrap XL mass spectrometer (Thermo Fisher Scientific,
Bremen, Germany) equipped with a nanoelectrospray ion
source.
For the mass spectrometry studies on the binding to
selected biological ligands, stock solutions of [1][CF3SO3]6,
Arg, His, Cys, and Lys, (each 0.286 mM) were prepared in
H2O. Solutions of [1][CF3SO3]6 were incubated with the
selected amino acid in a 1:10 molar ratio for 48 h at 37 C.
The samples were analysed in the positive ion mode with a
voltage of ?700 V applied to the glass emitter (New
Objective, Woburn, MA, USA). The tube lens was at
?150 V and the transfer capillary was held at 200 C.
Spectra were acquired in Fourier transform mass spectrom-
etry mode over an m/z range from 100 to 2,000 with a reso-
lution of 100,000 at m/z 400. Calibration of the instrument
was performed with ProteoMass LTQ/FT-Hybrid electro-
spray ionisation (ESI) positive mode calibration mix
(Supelco Analytical, Bellefonte, PA, USA). The Xcalibur
software package (version 2.0.7, Thermo Fisher Scientific)
was used for instrument control and data processing.
Results and discussion
Synthesis and characterisation of the metallaprism
The hexanuclear metallaprism [1][CF3SO3]6 (Fig. 1) was
prepared from the dinuclear complex [(p-cymene)2Ru2
(dhnq)Cl2] and tpt in the presence of silver tri-
fluoromethanesulfonate according to the literature method
[32]. The 1H NMR spectrum of [1]6? in D2O (Fig. S1) is
relatively simple and contains two doublets at d 8.51 and 7.87
assigned to the Ha and Hb protons of tpt, one singlet at 7.56
assigned to the 12 protons of dhnq, two doublets at d 5.81 and
5.47 assigned to the p-cymene ring protons and one septet at d
2.74, one singlet at d 1.81 and one doublet at d 1.20 for the
methyl and isopropyl groups of the p-cymene protons. The 13C
chemical shifts (obtained from 1H–13C heteronuclear single
quantum coherence and heteronuclear multiple bond corre-
lation NMR spectra) were found at d 171.0 (CO), 152.8 (CHa),
143.1 (Ctpt), 137.9 (CHq), 123.6 (CHb), 103.8 (Cp-cymene),
100.3 (Cp-cymene), 85.3 (CHp-cymene), 82.1 (CHp-cymene), 30.4
(CH(CH3)2), 21.3 (CH(CH3)2) and 16.3 ((CH3)p-cymene).
Interestingly, the spectrum in D2O showed an additional
set of resonances for tpt at d 7.87 and 6.52; the corre-
sponding 13C shifts are found at d 149.9 and 121.0 ppm,
respectively. These resonances seem to belong to a product
of hydrolysis of the tpt residue which is formed immedi-
ately after dissolving the metallaprism in D2O. In other
solvents such as dimethyl sulfoxide, these resonances do
not appear (Fig. S2), indicating that the presence of an
impurity or a side product can be excluded. In addition, the
DOSY spectrum of [1]6? in D2O (Fig. S3) clearly shows
that all resonances have the same diffusion coefficient, thus
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suggesting that the metallaprism remains intact and does
not disassemble in aqueous solution. In addition, the ESI
mass spectrum of [1][CF3SO3]6 exhibits only the expected
fragments of the metallaprism with four remaining tri-
fluoromethanesulfonate ions (Fig. S4). Therefore, it is
not clear how D2O interacts with the tpt panels of the
metallaprism [1]6?; however, hydrogen-bond interactions
between the triazine core of tpt and D2O might provide an
explanation.
Stability in aqueous solution
To evaluate and compare the stability of [1]6? in aqueous
solution with the stability of metallaprism [2]6? [21], 1 mg
[1][CF3SO3]6 was dissolved in 1.0 mL D2O, and the
sample was analysed by 1H NMR spectroscopy. To study
the behaviour of [1]6? in solutions containing chloride and
other anions, we dissolved [1][CF3SO3]6 in 50 mM D2O
solutions of NaCl and Na2CO3. In all cases,
1H NMR
spectra were recorded immediately after sample prepara-
tion, and every 2 h for 24 h (Fig. 2).
In the presence of chloride ions additional resonances
appear immediately after dissolving [1][CF3SO3]6. Typi-
cally, the tpt and dhnq resonances as well as the resonances
of the two methyl groups of the p-cymene ligand are
affected. These data are similar to the data found for
metallaprism [2]6? containing dhbq as a ligand [21],
indicating that both prisms have similar behaviour in saline
solution.
Different results were obtained when carbonate ions are
present in solution. Directly after [1][CF3SO3]6 is dissolved
in a D2O solution containing 50 mM Na2CO3, the
1H NMR
spectrum exhibits many additional resonances in the spectral
region of tpt and dhnq (Fig. S5). A second set of resonances
also appeared for the p-cymene resonances and the relative
intensity of this second set of resonances changes over time.
These experimental data suggest that the prism loses step-
wise the tpt and the dhnq ligands, which are replaced by
either OH- or CO3
- at the ruthenium atoms, as further
indicated by the 2D 1H DOSY spectrum (Fig. S6). These
results corroborate the behaviour of metallaprism [2]6?
upon the addition of carbonate ions [21]. Therefore, both
metallaprisms [1][CF3SO3]6 and [2][CF3SO3]6 are stable in
aqueous solutions for about 2 h in solutions containing
chloride ions, whereas they undergo a rapid dissociation in
solutions containing carbonate ions. Additionally, the sta-
bility of hexacationic metallaprisms as a function of the pH
was previously estimated for [2]6? [33]. The 1H NMR
spectra measured at 5 min, 1 h and 4 h in D2O with 50 mM
NaCl at pH 5.5 showed that the metallaprisms remain stable
for at least 4 h but slowly hydrolyse as described above.
Reactions with ascorbic acid and lactic acid
Most of the metallodrugs currently used in antitumour
therapy, such as carboplatin and cisplatin, are administered
intravenously and can therefore encounter various reactive
biomolecules in the bloodstream. The concentrations of
some biological molecules in the bloodstream [34] make
them potential binding partners for metallodrugs. In par-
ticular, serum proteins such as albumin and transferrin can
act in two different ways: the drugs bind to the proteins and
are selectively released once they are inside the cancer
cells, or these serum proteins may deactivate them even
before they reach their targets [35–39]. As such, ascorbic
acid, lactic acid, various amino acids and GSH were chosen
and were subjected to analysis with [1][CF3SO3]6.
The spectra of the mixture of [1]6? and lactic acid (ratio
1:10) over time were compared with the 1H NMR spectra
of free lactic acid and free [1]6?. The NMR spectra
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Fig. 1 Hexanuclear metallaprisms [1][CF3SO3]6 and [2][CF3SO3]6
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exhibited some changes for the resonances of the prism
(Fig. 3), probably due to hydrolysis. Analysis of the DOSY
spectrum after 24 h reveals, however, that no adduct
between lactic acid and the metallaprism has been formed
(Fig. S7), since the DOSY spectrum exhibits two distinct
set of resonances, one assignable to free lactic acid and the
other to the free metallaprism. These results suggest that
metallaprism [1]6? hydrolyses slightly faster in the pres-
ence of lactic acid but also that no strong interaction occurs
between these two components.
The results obtained for the reaction between [1]6? and
ascorbic acid contrast with those obtained with lactic acid.
Directly after the two components were mixed in a 1:6
ratio, the 1H resonances of the metallaprism remained
unchanged, but adjacent to the resonances of ascorbic acid
(d 3.75, 4.05 and 4.55) new resonances at d 4.75, 4.25, and
4.17 arose (Fig. 4). In agreement with the literature [40],
these resonances are assigned to dehydroascorbic acid. The
resonances of dehydroascorbic acid increase slightly in
intensity over time, whereas the resonances of the protons
associated with ascorbic acid decrease slightly in intensity.
After about 72 h equilibrium is reached, and the conversion
of ascorbic acid into dehydroascorbic did not proceed
further (Chart S1). The total amount of ascorbic acid
converted is about 4 %, which is slightly more than the
amount of ascorbic acid converted into dehydroascorbic
acid via autoxidation in D2O (1.3 % after 2 weeks; Chart
S2).
Analyses of the 2D 1H DOSY spectrum recorded after
72 h revealed that a reaction had occurred and that the
metallaprism had disassembled. Indeed, the 1H DOSY
NMR spectrum (Fig. 5) indicates that the two resonances
of tpt at d 9.11 and 9.23 no longer belong to the rest of the
prism. The DOSY spectrum also shows that no adduct is
formed between the metal centre and ascorbic acid or
dehydroascorbic acid, since the respective diffusion coef-
ficients are distinct. It seems, therefore, that metallaprism
[1]6? is able to slightly enhance the rate of oxidation of
ascorbic acid to dehydroascorbic acid, and that it also
simultaneously undergoes a partial disassembly with the
loss of both tpt moieties. Interestingly, these experiments
reveal that the oxidation of ascorbic acid is much slower
and incomplete compared with that for metallaprism [2]6?
and is also accompanied by the partial destruction of the
metallaprism, which was not observed with [2]6? [21]. In
addition [1]6? is dismembered in the presence of ascorbic
Fig. 2 Stability of [1]6?
monitored by 1H NMR
spectroscopy for 24 h. Left
[1]6? in D2O, right [1]
6? in D2O
with addition of 50 mM NaCl
Fig. 3 a 1H spectra of the mixture of [1]6? and lactic acid at 0, 12 and 24 h (bottom to top) and b a comparison of the spectrum of the mixture
after 24 h with the spectra of free [1]6? and free lactic acid (bottom to top)
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acid, and it follows that [1]6? can easily react with ascorbic
acid or water as compared with metallaprism [2]6?.
Reactions with Arg, Lys and His
Our recent investigations of metallaprism [2]6? [21]
showed that it behaves rather differently from other ruthe-
nium-based anticancer complexes [41]. In the same way,
[1]6? showed no interactions with amino acids that are
known to form stable complexes with ruthenium, such as
Met [42]. Table S1 gives an overview of the reactions of
[1]6? with different biomolecules. In accordance with
metallaprism [2]6? [21], the reactions between Arg, His and
Lys and [1]6? in D2O show significant changes in the NMR
spectra within 24 h, indicating that a reaction has occurred
in each case. Notably, new resonances appear adjacent to
the resonance of Ha for all three amino acids (Fig. 6).
Analysis of the various NMR spectra revealed that the
reactions of [1]6? with Arg, His and Lys are at first nearly
identical to the reactions obtained with metallaprism [2]6?
and suggest that chiral adducts are formed (Fig. 7). There
are, however, significant differences: whereas the reactions
were complete and occurred within minutes with metal-
laprism [2]6?, the reactions of [1]6? with Arg, His and Lys
occurred much more slowly and reached a different equi-
librium state. As shown in Fig. 6, the appearance of addi-
tional Ha resonances belonging to chelate adducts can be
clearly observed only after 12 h. For Arg and Lys, the
reactions are complete after about 24 h, as indicated by
the NMR spectra (Fig. S9). On the other hand, for His, the
NMR spectra obtained after 48 h once the steady state has
been reached (i.e. when no changes in either the intensity
or the chemical shifts of the resonances are observed) show
that the ratio between free His and the newly formed His
adduct is not 4:6 as expected if the reaction had been
complete. The spectra show that only about 17 % of His
has reacted with [1]6?, which is confirmed by the presence
of the resonances of the tpt and dhnq moieties in the NMR
spectra, which are otherwise absent when the reaction is
complete [21]. Taking into account the much longer reac-
tion time and the incomplete reaction of His, [1]6? appears
much less reactive than metallaprism [2]6? towards amino
acids with basic side chain residues. The high cytotoxic-
ity of [1]6? may appear surprising at first, since this
metallaprism is apparently more chemically inert than
metallaprism [2]6?. However, a recent study by Meier et al.
[43] suggests an inverse correlation between metallodrug–
protein interaction and cytotoxicity with regard to tumour
cells. Similarly, we have shown in a recent study that tri-
thiolato arene ruthenium complexes are highly cytotoxic
despite their inertness towards biomolecules such as amino
acids and nucleotides [44].
The formation of these adducts was confirmed by ESI
measurements and 2D 1H DOSY NMR spectra. The ESI
mass spectra (Fig. S10–S12) for the mixture of [1]6? and
the amino acids measured after an incubation time of 48 h
show in each case a peak which can be assigned to the
following adduct: [(p-cymene)Ru ? amino acid ? H]?
(Table 1).
The 2D 1H DOSY NMR spectra for mixtures of [1]6?
and Arg or Lys are similar: they both exhibit resonances
possessing a diffusion coefficient assignable to the ruthe-
nium–amino acid adduct and others attributable to the free
amino acid. According to the observations from the other
NMR spectra, the DOSY spectrum of the mixture [1]6? and
His displays three different diffusion coefficients, which
Fig. 4 1H spectrum of the mixture [1]6? and ascorbic acid at 5 min
(bottom). Adjacent to the resonances of ascorbic acid a new set of
resonances appears indicated by black arrows. These resonances
increase in intensity over time as can be seen in the spectrum
measured after 72 h (top)
Fig. 5 Two-dimensional 1H diffusion-ordered spectroscopy spectrum
of the mixture of [1]6? and ascorbic acid (ratio 1:6) after 72 h. The
partial disassembly of the prism is noticeable since the resonances of
2,4,6-tri(pyridine-4-yl)-1,3,5-triazine at d 9.11 and 9.23 have a
diffusion coefficient different from that of the other resonances of
the prism
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belong, respectively, to the newly formed adduct, the free
amino acid, and the intact metallaprism (Fig. S13–S15).
Reactions with Cys and GSH
The reactions between Cys and GSH with [1]6? were also
followed by 1D and 2D NMR spectroscopy as well as by
ESI mass spectrometry. For Cys, no perceptible changes in
the NMR spectra could be observed immediately after
mixing the two components in D2O. After about 12 h, the
1H NMR spectrum exhibits the set of resonances (d 3.18,
3.36 and 4.10) characteristic of cystine next to the reso-
nances of Cys (d 2.99, 3.07 and 3.97) [45]. The resonances
of cystine increase in intensity over time relative to the
resonances of Cys, but even after 2 weeks the oxidation is
still incomplete (Fig. S18). Compared with the autoxidation
of Cys in D2O with or without trifluoromethanesulfonate
ions present in the solution (Fig. S19), a higher amount of
Cys is, however, converted into cystine in the presence of
[1]6?, suggesting that metallaprism [1]6? acts as a catalyst
for this oxidation reaction.
Analyses of the DOSY spectrum suggests that once
formed, cystine reacts with a fragment of the metallaprism
(Fig. S17). Indeed, the various NMR spectra indicate that
the tpt and dhnq moieties are removed from the ruthenium
centre and that cystine coordinates to the remaining frag-
ment of the prism. As observed with Arg, His and Lys,
these findings suggest that cystine can act as a chelating
ligand for the ruthenium atom and can replace the tpt and
dhnq ligands in the initial prism. Interestingly, however,
Cys does not bind to the prism, as revealed by the DOSY
spectrum. These results are in stark contrast to the obser-
vation made by Wang et al. [22]. In the case of the
[(g6-biphenyl)RuCl(en)][PF6] complex (en is ethylenedia-
mine), they observed the formation of an adduct between the
ruthenium atom and both Cys and cystine. In our case the
shifts of cystine bound to the ruthenium centre (d 3.16, 3.34
and 4.09) are very similar to those of free cystine (d 3.22, 3.41
and 4.16) [45].
A plausible structure of the adduct formed upon the
addition of cystine was established by analysing the ESI
mass spectrum (Fig. 8). A characteristic peak is clearly
visible at m/z = 710.04, consistent with the formation of a
complex containing two ruthenium atoms per cystine, [2(p-
cymene)Ru ? cystine ? H]?. The formation of such a
diruthenium complex (Fig. 9) is rather surprising, since it
markedly differs from the behaviour of the other amino
acids with regard to [1]6? and from the results we have
obtained with metallaprism [2]6? [21].
The reaction of GSH with metallaprism [1]6? in a 6:1
ratio reveals a rather unexpected result, since the reso-
nances of Cys (GSH) at d 2.89 and 4.52 have completely
disappeared from the 1H NMR spectrum after only 24 h,
and only the resonances of cystine (GSSG, d 2.95, 3.23 and
4.67) are visible, indicating that the oxidation of GSH to
GSSG is completed after 24 h of incubation. Figure 10
Fig. 6 1H NMR spectra of [1]6? and Arg, His and Lys (left to right) recorded over time. After 12 h, the appearance of additional resonances near
the original Ha resonance can be clearly observed
Fig. 7 General structural formula of the chelate adduct formed upon
the addition of Arg, His and Lys
Table 1 Characteristic peaks observed in the electrospray ionisation
mass spectra for mixtures of [1]6? and Arg, [1]6? and His, and [1]6?
and Lys
m/z Proposed adduct
[1]6? ? Arg 409.12 [(p-cymene)Ru ? Arg ? H]?
[1]6? ? His 390.07 [(p-cymene)Ru ? His ? H]?
[1]6? ? Lys 381.11 [(p-cymene)Ru ? Lys ? H]?
For the structure of [1]6?, see Fig. 1
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shows a comparison of the two 2D 1H–1H correlation
spectra obtained directly after incubation and after 24 h.
The black arrows indicate the resonances of Cys, which
vanished completely after 24 h, as clearly shown in the red
spectrum. This result is surprising and strongly contrasts
with the results obtained for the oxidation of Cys in the
presence of [1]6?, which is not complete even after 14 days
(Fig. S18).
The DOSY NMR spectrum of the mixture recorded after
24 h (Fig. S20) indicates that metallaprism [1]6? loses both
the tpt and the dhnq ligand and coordinates to GSSG.
Rather surprisingly, the oxidation of GSH to GSSG is
completed faster in the presence of [1]6? than in the
presence of [2]6?. Also, the formation of an adduct could
not be observed with [2]6?. This very different behaviour
of [1]6? compared with [2]6? with regard to both Cys and
GSH might explain the significant differences in cytotox-
icity of the two metallaprisms (for [1]6?, IC50 = 2 lM
with regard to the A2780 cancer cell line, and for [2]6?,
IC50 = 23 lM).
Conclusions
In this study we have shown that metallaprism [1]6? reacts
with various biological ligands and forms different adducts.
As previously observed with metallaprism [2]6?, addition
of Arg, His and Lys displaces both the tpt and the dhnq
ligands, and chelate N,N,O arene ruthenium adducts are
formed. Solutions of [1]6? are also able to catalyse the
Fig. 8 Electrospray ionisation mass spectrum (positive mode) of [1][CF3SO3]6 and Cys (ratio 1:10) in H2O recorded after 48 h
Fig. 9 Suggested
[(p-cymene)Ru–cystine–Ru
(p-cymene)]? chelate complex
obtained upon the addition of
Cys to [1]6?
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oxidation of Cys to cystine and of GSH to GSSG. With
both oxidised molecules, different adducts are formed, and
these were not observed with previously investigated
metallaprism [2]6?. Furthermore, compared with metalla-
prism [2]6?, the oxidation of Cys is incomplete and occurs
much more slowly, whereas the oxidation of GSH is
completed within 24 h. The higher stability coupled with
the oxidation ability of [1]6? with regard to GSH might
explain the significant differences in cytotoxicity of the two
metallaprisms.
Interestingly, the kinetics of formation of the various
adducts is much slower with metallaprism [1]6? and
moreover the reaction is incomplete with His. At a first
glance, these differences could be attributed to the different
lipophilic characters of the metallaprisms, since the
replacement of dhbq by dhnq in [1]6? simultaneously
reduces the water solubility and increases the lipophilicity.
However, recent studies have shown that encapsulation of a
fluorescent pyrene molecule in these two metallaprisms
allows the uptake of the guest within cancer cells to be
monitored. Interestingly, the fluorescence observed after
24 h of incubation (2 lM concentration) of the host–guest
systems for A2780 cancer cells was almost equivalent,
suggesting similar internalisation and transport mechanisms
despite the structural differences of the two metallaprisms
[33, 46]. Therefore, our results clearly demonstrate that the
reactivity of ruthenium metallaprisms strongly depends on
the building blocks used. It is therefore supposed that these
ligands hamper the accessibility of the biological ligands to
the reactive ruthenium atom, since dhnq is bulkier than
dhbq (Fig. S21).
From our results, it is also obvious that the cytotoxicity
of the metallaprisms is not correlated to the reactivity,
since the results show that [1]6? is more cytotoxic but less
reactive than metallaprism [2]6?. To further support this
statement, we will investigate other ruthenium metallap-
risms with bulkier ligands such hexamethylbenzene in
place of p-cymene and compare the reactivity and espe-
cially the effects on the stability of the prism.
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